AbbVie – Hepatitis C Virus Infection

Access Program Information

This is an expanded access program (EAP) for eligible participants. This program is designed
to provide access to glecaprevir/ pibrentasvir prior to approval by the local regulatory
agency. Availability will depend on territory eligibility. Participating sites will be added
as they apply for and are approved for the EAP. A medical doctor must decide whether the
potential benefit outweighs the risk of receiving an investigational therapy based on the
individual patient’s medical history and program eligibility criteria.

Rare Disease: